{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T04:31:00Z","timestamp":1773376260002,"version":"3.50.1"},"reference-count":63,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University","award":["21618"],"award-info":[{"award-number":["21618"]}]},{"name":"Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University","award":["SHDC2020CR3020A"],"award-info":[{"award-number":["SHDC2020CR3020A"]}]},{"name":"Clinical Research Plan of SHDC","award":["21618"],"award-info":[{"award-number":["21618"]}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR3020A"],"award-info":[{"award-number":["SHDC2020CR3020A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: To identify the critical factors associated with the progression-free survival (PFS) and overall survival (OS) of high-grade glioma (HGG) in adults who have received standard treatment and establish a novel graphical nomogram and an online dynamic nomogram. Patients and Methods: This is a retrospective study of adult HGG patients receiving standard treatment (surgery, postoperative radiotherapy, and temozolomide (TMZ) chemotherapy) at Huashan Hospital, Fudan University between January 2017 and December 2019. We used uni- and multi-variable COX models to identify the significant prognostic factors for PFS and OS. Based on the significant predictors, graphical and online nomograms were established. Results: A total of 246 patients were enrolled in the study based on the inclusion criteria. The average PFS and OS were 22.99 \u00b1 11.43 and 30.51 \u00b1 13.73 months, respectively. According to the multi-variable COX model, age, extent of resection (EOR), and IDH mutation were associated with PFS and OS, while edema index (EI) was relevant to PFS. In addition, patients with IDH and TERT promoter co-mutations had longer PFSs and OSs, and no apparent survival benefit was found in the long-cycle TMZ adjuvant chemotherapy compared with the standard Stupp protocol. Based on these critical factors, a graphical nomogram and online nomogram were developed for predicting PFS and OS, respectively. The calibration curve showed favorable consistency between the predicted and actual survival rates. C-index and time-dependent AUC showed good discrimination abilities. Conclusions: We identified the significant predictors for the PFS and OS of HGG adults receiving standard treatment and established user-friendly nomogram models to assist neurosurgeons in optimizing clinical management and treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm12010196","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T03:03:31Z","timestamp":1672110211000},"page":"196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nomogram Model for Predicting the Prognosis of High-Grade Glioma in Adults Receiving Standard Treatment: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-1329","authenticated-orcid":false,"given":"Peng","family":"Du","sequence":"first","affiliation":[{"name":"Department of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"Department of Radiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xionggang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiology, Jiahui International Hospital, Shanghai 200233, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Computer and Information Technology, Beijing Jiaotong University, Beijing 100044, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shanghai Gamma Hospital, Shanghai 200040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aihong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoying","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: A \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stylli, S.S. (2020). Novel Treatment Strategies for Glioblastoma. Cancers, 12.","DOI":"10.3390\/cancers12102883"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4103\/jcrt.JCRT_233_19","article-title":"Prognostic factors and clinical nomogram predicting survival in high-grade glioma","volume":"17","author":"Tunthanathip","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","article-title":"Current and future strategies for treatment of glioma","volume":"40","author":"Bush","year":"2017","journal-title":"Neurosurg. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11060-016-2110-4","article-title":"Maximizing safe resection of low- and high-grade glioma","volume":"130","author":"Berger","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fneur.2012.00140","article-title":"The value of glioma extent of resection in the modern neurosurgical era","volume":"3","author":"Hardesty","year":"2012","journal-title":"Front. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10143-014-0592-0","article-title":"Intraoperative assistive technologies and extent of resection in glioma surgery: A systematic review of prospective controlled studies","volume":"38","author":"Barbosa","year":"2015","journal-title":"Neurosurg. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","volume":"2","author":"Brown","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"900382","DOI":"10.3389\/fonc.2022.900382","article-title":"Surgical Management of Malignant Glioma in the Elderly","volume":"12","author":"Klingenschmid","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/01.nrl.0000250928.26044.47","article-title":"Glioma therapy in adults","volume":"12","author":"Norden","year":"2006","journal-title":"Neurologist"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000470","article-title":"Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT","volume":"42","author":"Sutera","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2741\/1727","article-title":"Chemotherapy and novel therapeutic approaches in malignant glioma","volume":"10","author":"Desjardins","year":"2005","journal-title":"Front. Biosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","article-title":"MGMT Status as a Clinical Biomarker in Glioblastoma","volume":"6","author":"Butler","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?","volume":"6","author":"Weller","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-12048-5_1","article-title":"Epidemiology of gliomas","volume":"163","author":"Ostrom","year":"2015","journal-title":"Cancer Treat. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.path.2021.05.003","article-title":"Molecular Pathology of Gliomas","volume":"14","author":"Galbraith","year":"2021","journal-title":"Surg. Pathol. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrclinonc.2016.204","article-title":"Advances in the molecular genetics of gliomas-implications for classification and therapy","volume":"14","author":"Reifenberger","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13311-017-0519-x","article-title":"Glioma Subclassifications and Their Clinical Significance","volume":"14","author":"Chen","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nec.2017.05.003","article-title":"Intraoperative MRI and Maximizing Extent of Resection","volume":"28","author":"Rao","year":"2017","journal-title":"Neurosurg. Clin. N. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Huang, B., Yu, Z., and Liang, R. (2021). Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02461-9"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"779491","DOI":"10.3389\/fonc.2021.779491","article-title":"A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma","volume":"11","author":"Attarian","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-012-0826-3","article-title":"Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme","volume":"108","author":"Singh","year":"2012","journal-title":"J. Neurooncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","article-title":"Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors","volume":"20","author":"Capper","year":"2010","journal-title":"Brain Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"\u015aledzi\u0144ska, P., Bebyn, M.G., Furtak, J., Kowalewski, J., and Lewandowska, M.A. (2021). Prognostic and Predictive Biomarkers in Gliomas. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910373"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2583","DOI":"10.1097\/MD.0000000000002583","article-title":"Isocitrate Dehydrogenase (IDH)1\/2 Mutations as Prognostic Markers in Patients With Glioblastomas","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine"},{"key":"ref_36","first-page":"188","article-title":"Increased RLIP76 expression in IDH1 wild-type glioblastoma multiforme is associated with worse prognosis","volume":"43","author":"Wang","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1002\/jcb.26699","article-title":"ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study","volume":"119","author":"Romano","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrneurol.2014.100","article-title":"MGMT testing\u2014The challenges for biomarker-based glioma treatment","volume":"10","author":"Wick","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fonc.2019.01547","article-title":"O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy","volume":"9","author":"Yu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-022-03955-3","article-title":"Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma","volume":"157","author":"Haque","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sareen, H., Ma, Y., Becker, T.M., Roberts, T.L., de Souza, P., and Powter, B. (2022). Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23168835"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11060-019-03358-x","article-title":"Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival","volume":"146","author":"Schaff","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcp.25896","article-title":"The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials","volume":"233","author":"Binabaj","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.18632\/oncotarget.1765","article-title":"Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas","volume":"5","author":"Killela","year":"2014","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s40478-020-01078-2","article-title":"TERT promoter mutation confers favorable prognosis regardless of 1p\/19q status in adult diffuse gliomas with IDH1\/2 mutations","volume":"8","author":"Arita","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1038\/bjc.2014.538","article-title":"TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations","volume":"111","author":"Gleize","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_47","first-page":"vdaa114","article-title":"TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma","volume":"2","author":"Kikuchi","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/neuonc\/nou158","article-title":"TERT promoter mutations: A novel independent prognostic factor in primary glioblastomas","volume":"17","author":"Simon","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1212\/WNL.0000000000000814","article-title":"Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes","volume":"83","author":"Boisselier","year":"2014","journal-title":"Neurology"},{"key":"ref_50","first-page":"394","article-title":"Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy","volume":"19","author":"Nguyen","year":"2017","journal-title":"Neuro Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00401-013-1163-0","article-title":"TERT promoter mutations in primary and secondary glioblastomas","volume":"126","author":"Nonoguchi","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/nov010","article-title":"Prognostic quality of activating TERT promoter mutations in glioblastoma: Interaction with the rs2853669 polymorphism and patient age at diagnosis","volume":"17","author":"Ghanim","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1111\/cas.14597","article-title":"A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas","volume":"111","author":"Higa","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors","volume":"372","author":"Lachance","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3340\/jkns.2011.49.1.26","article-title":"Peritumoral brain edema in meningiomas: Correlation of radiologic and pathologic features","volume":"49","author":"Kim","year":"2011","journal-title":"J. Korean Neurosurg. Soc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3174\/ajnr.A6638","article-title":"Effect of Piezo1 Overexpression on Peritumoral Brain Edema in Glioblastomas","volume":"41","author":"Qu","year":"2020","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/neuonc\/nov119","article-title":"Intratumoral heterogeneity in glioblastoma: Don\u2019t forget the peritumoral brain zone","volume":"17","author":"Clavreul","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_58","first-page":"1101","article-title":"Histopathological findings in the peritumoral edema area of human glioma","volume":"30","author":"Wang","year":"2015","journal-title":"Histol. Histopathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"110423","DOI":"10.1016\/j.ejrad.2022.110423","article-title":"Spatial heterogeneity of edema region uncovers survival-relevant habitat of Glioblastoma","volume":"154","author":"Yang","year":"2022","journal-title":"Eur. J. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jocn.2021.04.042","article-title":"The Prognostic Role of Peritumoral Edema in Patients with Newly Diagnosed Glioblastoma: A Retrospective Analysis","volume":"89","author":"Zhang","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_61","first-page":"48","article-title":"Nomograms for Predicting the Overall and Cancer-Specific Survival of Patients with High-Grade Glioma: A Surveillance, Epidemiology, and End Results Study","volume":"30","author":"Xia","year":"2020","journal-title":"Turk Neurosurg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"108609","DOI":"10.1016\/j.ejrad.2019.07.010","article-title":"Improving survival prediction of high-grade glioma via machine learning techniques based on MRI radiomic, genetic and clinical risk factors","volume":"120","author":"Tan","year":"2019","journal-title":"Eur. J. Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/j.wneu.2022.05.039","article-title":"A Nomogram for Predicting Early Recurrence in Patients with High-Grade Gliomas","volume":"164","author":"Zhou","year":"2022","journal-title":"World Neurosurg."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:18Z","timestamp":1760147538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/1\/196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["jcm12010196"],"URL":"https:\/\/doi.org\/10.3390\/jcm12010196","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}